Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "2022"

1420 News Found

Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
News | August 14, 2022

Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr

The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.


SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
News | August 14, 2022

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.


Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP
Drug Approval | August 13, 2022

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP

The product will be manufactured at Lupin’s facility in Goa, India.


Vascular experts establish appropriate use of IVUS in peripheral interventions
News | August 13, 2022

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions


Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr
News | August 12, 2022

Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr

The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.


Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr
News | August 12, 2022

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.


Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr
News | August 11, 2022

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.


IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr
News | August 11, 2022

IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr

The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.